.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,643,553

« Back to Dashboard

Details for Patent: 5,643,553

Title: Stable microbubbles suspensions injectable into living organisms
Abstract:Gas or air filled microbubble suspensions in aqueous phases usable as imaging contrast agents in ultrasonic echography. They contain laminarized surfactants and, optionally, hydrophilic stabilizers. The laminarized surfactants can be in the form of liposomes. The suspensions are obtained by exposing the laminarized surfactants to air or a gas before or after admixing with an aqueous phase.
Inventor(s): Schneider; Michel (Troinex, CH), Bichon; Daniel (Montpellier, FR), Bussat; Philippe (Collonges S/Saleve, FR), Puginier; Jerome (Le Chable-Beaumont, FR), Hybl-Sutherland; Eva (Wiesbaden, DE)
Assignee: Bracco International B.V. (NL)
Filing Date:Sep 26, 1995
Application Number:08/534,198
Claims:1. A composition suitable for injection into the bloodstream and body cavities of living beings, comprising a suspension of stabilized air or gas microbubbles in a physiologically acceptable aqueous carrier phase having one or more dissolved or dispersed surfactants, at least one of said surfactants being a film forming saturated phospholipid present in the composition at least partially in lamellar or laminar form.

2. The composition of claim 1, wherein the lamellar surfactant is in the form of mono- or pluri-molecular membrane layers.

3. The composition of claim 1, containing about 10.sup.8 -10.sup.9 bubbles of 0.5-10 .mu.m size/ml.

4. The composition of claim 1, wherein said saturated phospholipid is selected from the group consisting of lecithins, phosphatidic acid, phosphatidyl-choline, phosphatidyl-ethanolamine, phosphatidyl-serine, phosphatidyl-glycerol, phosphatidyl-inositol, cariolipin and sphyngomyelin.

5. The composition of claim 1, and further comprising a substance affecting the properties of liposomes selected from the group consisting of phosphatidyl-glycerol, dicetyl-phosphate, cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, tocopterol, propyl gallate, ascorbyl palmitate and butylated hydroxy-toluene.

6. The composition of claim 1, and further comprising a dissolved viscosity enhancer or stabilizer selected from the group consisting of linear and cross-linked poly- and oligo-saccharides, sugars, hydrophilic polymers and iodinated compounds in a weight ratio to the surfactants of between about 1:5 to 100:1.

7. The composition of claim 6, wherein said iodinated compound is Iopamidol.

8. The composition of claim 1, wherein the surfactants comprise up to 50% by weight of non-laminar surfactants selected from the group consisting of fatty acids, ester and ethers of fatty acids and alcohols with polyols.

9. The composition of claim 8, wherein the non-laminar surfactant is selected from the group consisting of polyalkylene glycols, polyalkylenated sugars and polyalkylenated glyerol.

10. A method for the preparation of a composition as defined in claim 1, said method comprising the steps of:

(a) selecting at least one film forming surfactant and converting it into lamellar form;

(b) contacting the surfactant in lamellar form with air or an adsorbable or entrapable gas for a time sufficient for that air or gas to become bound by said surfactant; and

(c) admixing the surfactant in lamellar form with an aqueous liquid carrier, to form a stable dispersion of air or gas microbubbles in said liquid carrier.

11. The method of claim 10, wherein step (c) is performed before step (b), step (b) being effected by introducing pressurized air or gas into the liquid carrier and thereafter releasing the pressure.

12. The method of claim 10, wherein step (c) is brought about by gentle mixing or the components with no shaking, whereby air or as bound to the lamellar surfactant in step (b) develops into a suspension of stable microbubbles.

13. The method of claim 10, wherein the aqueous liquid carrier contains dissolved therein stabilizer compounds selected from the group consisting of hydrosoluble proteins, polypeptides, sugars, poly- and oligo-saccharides and hydrophilic polymers.

14. The method of claim 10, wherein step (a) is effected by coating the surfactant onto particles of soluble or insoluble materials, wherein step (b) is effected by letting the coated particles stand for a while under air or gas and step (c) is effected by admixing the coated particles with an aqueous liquid carrier.

15. The method of claim 10, wherein step (a) is effected by sonicating or homogenizing under high pressure an aqueous solution of film forming lipids, leading, at least partly, to the formation of liposomes.

16. The method of claim 15, wherein step (b) is effected by freeze-drying the liposome containing solution and contacting the resulting freeze-dried product with air or a gas.

17. The method of claim 16, wherein in step (b) the liposome containing solution contains hydrophilic stabilizers.

18. The method of claim 15, wherein the aqueous solution of film forming lipids also contains viscosity enhancers or stabilizers selected from the group consisting of hydrophilic polymers and carbohydrates in weight ratio relative to the lipids of between 1:5 and 100:1.

19. The composition of claim 4, wherein in addition to phospholipids the composition comprises a non-ionic surfactant.

20. The composition of claim 19, wherein the non-ionic surfactant is polyoxyethylene-polyoxypropylene copolymer.

21. The composition of claim 20, wherein the non-ionic surfactant is present in an amount of up to 50% by weight of the total amount of surfactants in the composition.

22. The composition of claim 21, wherein the non-ionic surfactant is present in an amount of up to 30% by weight of the total amount of surfactants in the composition.

23. The composition of claim 22, wherein the non-ionic surfactant is present in an amount of up to 2.5% by weight of the total amount of surfactants in the composition.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc